<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02133248</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0076</org_study_id>
    <nct_id>NCT02133248</nct_id>
  </id_info>
  <brief_title>Identification of Donor Specific B Cells and Antibody Mediated Rejection</brief_title>
  <official_title>Identification of Donor Specific B Cells Will Positively Affect Monitoring and Treatment of Donor Specific Antibodies and Antibody Mediated Rejection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many people who are on the wait list for a kidney transplant have harmful antibodies, called
      donor specific antibodies (DSA), which will attack foreign tissue such as the transplanted
      organ. These people are considered to be&quot;sensitized&quot;. Prior to receiving a kidney, these
      patients undergo desensitization treatments to remove these harmful antibodies. Levels of DSA
      are measured after desensitization, but the cells that produce the DSA, donor specific B
      cells (DSB), have not generally been measured. Additionally, if a person experiences chronic
      rejection due to antibodies they are also desensitized, but only the DSA are measured. This
      study will measure the DSA and, using new techniques, the DSB in two study groups: those who
      are receiving an organ and those experiencing chronic antibody mediated rejection after
      receiving an organ. The hypothesis is people with higher levels of DSB after desensitization
      are more likely to develop antibody mediated rejection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients that are sensitized, who have panel reactive antibodies (PRAs) &gt; 20%, comprise a
      disproportionate and increasing cluster on the wait list (33%), and have to wait longer to
      receive a transplant than non-sensitized patients. By 36 months on the wait list, 10% died
      before receiving a transplant. Those who do receive transplants require desensitization. The
      current desensitization protocols include anti-CD20 monoclonal antibody to remove B cells, a
      proteasome inhibitor to eliminate plasma cells and plasma exchange and/or intravenous
      immunoglobulin (IVIG) to remove pre-formed donor specific antibodies (DSA). The success of
      these protocols can be measured using single antigen bead (SAB) luminex technology. These
      desensitization protocols have been shown to significantly decrease mean fluorescence
      intensity (MFI). Desensitization protocols typically are more effective in removing
      antibodies that recognize HLA Class I molecules than those that recognize HLA Class II
      molecules. Unfortunately, even after pre-conditioning, sensitized patients are more likely to
      develop antibody mediated rejection (ABMR) than patients that do not have donor specific
      antibodies prior to transplant. Currently, serum levels of DSA are measured after
      desensitization, but not donor specific B cells (DSB). It is possible that B cells and/or
      plasma cells remain after treatment. Donor specific B cells, upon transplant and the
      accompanying exposure to antigen, can be re-stimulated to both produce antibody and also to
      develop into plasma cells which produce antibody. Therefore, potentially a better means of
      determining whether desensitization has been successful would be to look at both the DSA
      level using SAB technology as described above and to look at DSB to determine if these cells
      have been adequately cleared by the desensitization protocol.

      Specific Aim 1 Hypothesis: Patients who have adequate clearance of serum DSA, but who still
      have significant populations of DSB are more likely to develop ABMR.

      In Specific Aim 1, the investigators will utilize cutting edge technology to observe levels
      of anti-HLA antibodies, particularly donor specific antibodies, present in sensitized
      patients by staining DSB with HLA class I tetramers. This method allows enumeration and
      characterization of the source of DSA, the DSB. The investigators will determine the number
      of DSB and donor specific plasma cells (DSPC) prior to and after desensitization as well as
      later post transplant. In addition, the investigators will look at the phenotype and
      activation state of the DSB prior to transplant and after transplant. HLA class I tetramers
      are MHC class I molecules of a particular allele which are refolded with a peptide in the
      peptide binding groove, biotinylated on the C terminal tail and tetramerized using
      streptavidin conjugated to a fluorophore such as phycoerythrin (PE). Similarly, HLA class II
      tetramers are made of MHC class II alleles. B cells retain membrane bound antibody which has
      the exact specificity of the soluble antibodies that it also produces. The tetramers will
      bind only to B cells that have antibodies against that specific HLA class I allele on the
      surface, since the binding is determined only by the specificity of the antibody. At the same
      time, the cells will be stained with other markers to determine the activation state and
      phenotype of the DSB. This assay is done using flow cytometry. Additionally, the
      investigators will measure BAFF and APRIL cytokine levels by Elisa at all time points. These
      cytokines are closely related to B cell development. There is data to suggest that BAFF is
      elevated after some forms of desensitization, which could enhance new B cell development.

      Specific Aim 1 Hypothesis: Patients who have adequate clearance of serum DSA, but who still
      have significant populations of DSB are more likely to develop ABMR.

      In Specific Aim 1, the investigators will utilize cutting edge technology to observe levels
      of anti-HLA antibodies, particularly donor specific antibodies, present in sensitized
      patients by staining DSB with HLA class I tetramers. This method allows enumeration and
      characterization of the source of DSA, the DSB. The investigators will determine the number
      of DSB and donor specific plasma cells (DSPC) prior to and after desensitization as well as
      later post transplant. In addition, the investigators will look at the phenotype and
      activation state of the DSB prior to transplant and after transplant. HLA class I tetramers
      are MHC class I molecules of a particular allele which are refolded with a peptide in the
      peptide binding groove, biotinylated on the C terminal tail and tetramerized using
      streptavidin conjugated to a fluorophore such as phycoerythrin (PE). Similarly, HLA class II
      tetramers are made of MHC class II alleles. B cells retain membrane bound antibody which has
      the exact specificity of the soluble antibodies that it also produces. The tetramers will
      bind only to B cells that have antibodies against that specific HLA class I allele on the
      surface, since the binding is determined only by the specificity of the antibody. At the same
      time, the cells will be stained with other markers to determine the activation state and
      phenotype of the DSB. This assay is done using flow cytometry. Additionally, we will measure
      BAFF and APRIL cytokine levels by Elisa at all time points. These cytokines are closely
      related to B cell development. There is data to suggest that BAFF is elevated after some
      forms of desensitization, which could enhance new B cell development.

      The investigators will obtain a blood draw from subjects once consent is obtained and utilize
      this sample to establish a baseline of B cells that produce antibodies that recognize HLA
      class I tetramers of the same type as those previously identified by SAS anti-HLA antibody
      analysis. Immediately prior to and after the patient receives a transplant, the SAB anti-HLA
      antibody analysis, tetramer analysis, and BAFF/APRIL Elisas will be repeated. Analyses will
      also be performed between 6 weeks and 2 months after transplant.

      Specific Aim 2 Hypothesis: During chronic rejection, patients who respond well to
      desensitization and who are able to maintain tolerance after desensitization will have fewer
      residual DSB.

      In Specific Aim 2, the investigators will utilize the same technology to quantify and
      characterize DSA and DSB when a patient experiences chronic rejection due to ABMR. In this
      case, the patient may not have had DSA when transplanted, but developed de novo DSA (dnDSA)
      after transplant, causing rejection. Or the patient may have had DSA, been desensitized
      successfully, maintained tolerance for a period of time, then either lost tolerance or
      developed dnDSA. The timelines will be similar to specific aim 1 - the investigators will
      take samples at the following timepoints: upon diagnosis of ABMR, 1 week after
      desensitization, then 2 to 3 months after desensitization to look for rebound.

      In addition to enrollment of new subjects, the investigators will also enroll healthy normal
      individuals to serve as controls.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Donor specific B (DSB) cell populations are reduced after desensitization.</measure>
    <time_frame>1 week post desensitization treatment</time_frame>
    <description>The primary objective of this study is to determine whether desensitization results in not only a decrease in anti-HLA antibodies, but also a decrease in donor specific B cell populations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Donor specific B (DSB) cell populations are reduced after desensitization.</measure>
    <time_frame>6 weeks-3 months post desensitization</time_frame>
    <description>The primary objective of this study is to determine whether desensitization results in not only a decrease in anti-HLA antibodies, but also a decrease in donor specific B cell populations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of DSB to incidence of antibody mediated rejection</measure>
    <time_frame>12 months post desensitization</time_frame>
    <description>The secondary objective of this study is to correlate numbers and/or phenotypes of DSB remaining after desensitization to occurrence, for transplant recipients) or recurrence (for recipients with chronic antibody mediated rejection (ABMR)) of ABMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-cell activating factor (BAFF) levels increase after desensitization</measure>
    <time_frame>1 week post desensitization</time_frame>
    <description>Determine whether BAFF levels are increased in sensitized subjects, as well as to determine if this cytokines are increased post desensitization, as has been suggested in the literature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-cell activating factor (BAFF) levels increase after desensitization</measure>
    <time_frame>6 weeks-3 months post desensitization</time_frame>
    <description>Determine whether BAFF levels are increased in sensitized subjects, as well as to determine if this cytokines are increased post desensitization, as has been suggested in the literature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A proliferation inducing ligand (APRIL) levels increase after desensitization</measure>
    <time_frame>1 week post desensitization</time_frame>
    <description>Determine whether APRIL levels are increased in sensitized subjects, as well as to determine if this cytokines are increased post desensitization, as has been suggested in the literature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A proliferation inducing ligand (APRIL) levels increase after desensitization</measure>
    <time_frame>6 weeks-3 months post desensitization</time_frame>
    <description>Determine whether APRILlevels are increased in sensitized subjects, as well as to determine if this cytokines are increased post desensitization, as has been suggested in the literature.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sensitized Kidney Transplant Recipients</condition>
  <arm_group>
    <arm_group_label>kidney recipient waitlist</arm_group_label>
    <description>Subjects on waitlist for Kidney transplant who are sensitized</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic antibody mediated rejection</arm_group_label>
    <description>Kidney transplant recipient who are diagnosed with chronic antibody mediated rejection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>Normal subjects-no kidney transplant or chronic rejection</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Frozen peripheral blood mononucleated cells and plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Aim 1: Subjects on the wait list for kidney transplantation who are patients of the
        University of Wisconsin Hospital and Clinics (UWHC) and are identified as sensitized Aim 2:
        Kidney transplant recipients who are having a clinically indicated biopsy due to suspected
        antibody mediated rejection and are patients of the UWHC Both aims: Control subjects
        recruited from the University of Wisconsin Office of Clinical Trials control recruitment
        database
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 inclusive

          -  Patients on UWHC Kidney Transplant waitlist identified as sensitized or

          -  UWHC kidney transplant recipient patients diagnosed with antibody mediated rejection

        Exclusion Criteria:

          -  Inability to provide informed consent to participate in study

          -  Diagnosed with an autoimmune disorder or kidney problems, currently on
             immunosuppressive or immunomodulatory medication, or any current malignancies (healthy
             controls only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arjang Djamali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin Madison School of Medicine and Public Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arjang Djamali, MD</last_name>
    <phone>608-262-9306</phone>
    <email>axd@medicine.wisc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nancy Wilson Schlei, PhD</last_name>
    <phone>608-263-3369</phone>
    <email>nawilson@medicine.wisc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arjang Djamali, MD</last_name>
      <phone>608-262-9306</phone>
      <email>axd@medicine.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nancy WilsonSchlei, PhD</last_name>
      <phone>608-263-3369</phone>
      <email>nawilson@medicine.wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Arjang Djamali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Niederhaus SV, Muth B, Lorentzen DF, Wai P, Pirsch JD, Samaniego-Picota M, Leverson GE, D'alessandro AM, Sollinger HW, Djamali A. Luminex-based desensitization protocols: the University of Wisconsin initial experience. Transplantation. 2011 Jul 15;92(1):12-7. doi: 10.1097/TP.0b013e31821c93bb.</citation>
    <PMID>21512428</PMID>
  </reference>
  <reference>
    <citation>Lobashevsky AL, Higgins NG, Rosner KM, Mujtaba MA, Goggins WC, Taber TE. Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab. Transplantation. 2013 Jul 27;96(2):182-90. doi: 10.1097/TP.0b013e3182962c84.</citation>
    <PMID>23778648</PMID>
  </reference>
  <reference>
    <citation>Djamali A, Muth BL, Ellis TM, Mohamed M, Fernandez LA, Miller KM, Bellingham JM, Odorico JS, Mezrich JD, Pirsch JD, D'Alessandro TM, Vidyasagar V, Hofmann RM, Torrealba JR, Kaufman DB, Foley DP. Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients. Kidney Int. 2013 Jun;83(6):1185-92. doi: 10.1038/ki.2013.44. Epub 2013 Feb 27.</citation>
    <PMID>23447068</PMID>
  </reference>
  <reference>
    <citation>Tait BD, SÃ¼sal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, Reed EF, Bray RA, Campbell P, Chapman JR, Coates PT, Colvin RB, Cozzi E, Doxiadis II, Fuggle SV, Gill J, Glotz D, Lachmann N, Mohanakumar T, Suciu-Foca N, Sumitran-Holgersson S, Tanabe K, Taylor CJ, Tyan DB, Webster A, Zeevi A, Opelz G. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013 Jan 15;95(1):19-47. doi: 10.1097/TP.0b013e31827a19cc.</citation>
    <PMID>23238534</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2014</study_first_submitted>
  <study_first_submitted_qc>May 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2014</study_first_posted>
  <last_update_submitted>June 6, 2016</last_update_submitted>
  <last_update_submitted_qc>June 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>donor specific antibodies</keyword>
  <keyword>B cells</keyword>
  <keyword>antibody mediated rejection</keyword>
  <keyword>kidney transplant</keyword>
  <keyword>desensitization</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

